FOLH1 and pachyonychia congenita: The preclinical and clinical studies presented in this research demonstrated that the iPSMA-BN radioligands, [99mTc]Tc-iPSMA-BN and [177Lu]Lu-iPSMA-BN, have the ability to detect in vivo expression of both PSMA and GRP receptors for potential theranostic application in patients with metastatic PC.